BLUE News and Press, bluebird bio Inc. From 02/16/21

bluebird bio (BLUE) has lost ~25.8% in premarket after the company announced the temporary suspension of two clinical trials for its gene therapy candidate, LentiGlobin, and the marketing of ZYNTEGLO™ gene therapy, approved in Europe for transfusion-dependent ;...

bluebird bio, Inc. (Nasdaq: BLUE) announced today that the company has placed its Phase 1/2 (HGB-206) and Phase 3 (HGB-210) studies of LentiGlobin gene therapy for sickle cell disease (SCD) (bb1111) on a temporary suspension due to a reported Suspected Unexpected Serious Adverse...

BOSTON, MA / ACCESSWIRE / February 12, 2021 / Block & Leviton LLP ( www.blockleviton.com ), a national securities litigation firm, announces that a lawsuit for violation of the federal securities laws has been filed against bluebird bio, Inc. (NASDAQ:BLUE) and certain of its executives. ...

Many stocks are in bubble mode, and usually it's not difficult to avoid them. But which stocks are dangerous without that being obvious? Just like last month I made a list of overvalued stocks with negative smooth momentum and high trading volume. Avoid these, at least for the nex...

A biotech that has been developing new treatments for cancer and cures for severe genetic diseases will soon become a pair of more-focused independent companies. On Monday, bluebird bio (NASDAQ: BLUE) announced its intent to spin off its oncology business. The transition is expe...

Bluebird bio (BLUE) rises 4% in premarket as it confirms its plans to separate its oncology business into differentiated and independent publicly traded company by last quarter of this year. This spin out of Oncology Newco is anticipated to be tax- free to shareholders.The company w...

Severe Genetic Disease business will remain the focus of bluebird bio, Inc.; separation expected to result in two independent, publicly traded companies by year-end 2021 Separation designed to unlock value through improved operational execution, organizational focus, tailored ...

Imara (IMRA) closed in red, down 38% yesterday as investors apparently saw the company's sickle cell data lacked benefit when compared to its peers.Data showed that IMR-687 had no meaningful impact on key measures like fetal hemoglobin ((HbF)) or hemoglobin levels when taken by itse...

bluebird had a rough 2020 but we are quickly approaching several key catalysts in 2021 that will transform the company's outlook and possibly inject some momentum into the share price. ZYNTEGLO has conditional approval in the EU for those with transfusion-dependent beta-thalassemia. T...

I estimate the fair value for BLUE between $5-7 billion based on similar acquisitions. 2021 could be an inflection point with the anticipated approval of the company's multiple myeloma treatment. BLUE's most recent share issuance caused significant dilution, but the value is below...